作者:John A. Easter、Richard C. Burrell、Samuel J. Bonacorsi、Balu Balasubramanian
DOI:10.1002/jlcr.1620
日期:2009.8
Cytochrome P450 (CYP) enzymes are responsible for much of the phase I oxidative metabolism observed in vivo. Many important pharmaceutical compounds are metabolized by CYP. Co-administration of a drug with another agent can alter the efficacy or the toxicity, especially in cases where drug clearance depends primarily on the CYP metabolism. Compounds that induce or inhibit the CYP activity are often used in drug–drug interaction studies. Midazolam is one such compound that is routinely used in drug–drug interaction studies because it is a known substrate for CYP3A enzymes. The synthesis of this important tool molecule has been documented, but unfortunately a detailed preparation of carbon-14-labelled midazolam has not been reported in the literature. This paper describes a two-step synthesis leading to [14C]midazolam. A total of 4.5 mCi of [14C]midazolam was obtained having a specific activity of 120.1 µCi/mg (39.12 mCi/mmol). The radiochemical purity as determined by HPLC was 99.8% and the overall radiochemical yield was 9%. Copyright © 2009 John Wiley & Sons, Ltd.
细胞色素 P450(CYP)酶负责体内观察到的大部分 I 期氧化代谢。许多重要的药物化合物都通过 CYP 进行代谢。一种药物与另一种药物合用会改变药效或毒性,尤其是在药物清除主要依赖于 CYP 代谢的情况下。诱导或抑制 CYP 活性的化合物常用于药物相互作用研究。咪达唑仑(Midazolam)就是这样一种化合物,由于它是 CYP3A 酶的已知底物,因此被常规用于药物相互作用研究。这种重要工具分子的合成方法已有文献记载,但遗憾的是,碳 14 标记的咪达唑仑的详细制备方法尚未见文献报道。本文介绍了[14C]咪达唑仑的两步合成法。总共获得了 4.5 mCi 的[14C]咪达唑仑,其比活度为 120.1 µCi/mg(39.12 mCi/mmol)。经 HPLC 测定,放射化学纯度为 99.8%,总放射化学收率为 9%。Copyright © 2009 John Wiley & Sons, Ltd. All Rights Reserved.